AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06314984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group II B (Comfort-in Jet Injector)
Description: The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the maxilla by the needleless Comfort-in jet injector \[Infiltration\].
Study NCT04698057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The aim of the study is to validate the desescalation of the treatment to stop ciprofloxacin prescription that may not impact the outcome of the patients but add toxicity and antibiotics selection. Placebo will be administred in the experimental arm
Study NCT04698057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: Will be administred to all patients
Study NCT04698057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Clavulanate
Description: Will be administred to all patients
Study NCT04698057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Will be administred to patients in the standard of care arm
Study NCT05559294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Development of Early Childhood Education and Care Staff for Science
Description: A nine-month program consisting of three e-learning modules and three group workshops
Study NCT05559294 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and care as Usual (ECAU)
Description: Active control
Study NCT04764396 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)
Description: The fine needle biopsy (FNB) needle will be flushed with 1 mL of heparin (100 USP/mL) and then flushed with air. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed with 1 mL of heparin (100 USP/mL) and flushed with air before next pass is made.
Study NCT04764396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: FNB will be performed as current standard methods in the medical procedure unit without the use of heparin priming. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed saline and or air as per current standards of care.
Study NCT05008679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: at a dose of 75 mg twice daily
Study NCT06433180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of fecal microbiota transplantation ( FMT capsules)
Description: Oral, capsulized, frozen fecal microbiota transplantation FMT delivering approximatively 24 g of stools taken in one day in two separate meals. Administration of the FMT after colon cleaning.
Study NCT06433180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of the sham (PLACEBO)
Description: Oral, capsulized, frozen capsules without fecal matter but containing cryopreservation solution will be administered at the same volume and same time point as in the experimental group. Taken in one day in two separate meals. Administration of the sham after colon cleaning.
Study NCT04717804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIP CT
Description: An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
Study NCT04717804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FB (Free-Breathing) CT
Description: A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
Study NCT05614297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Knee joint laxity test
Description: Patients seen in an outpatient clinic in connection with an ACL injury or in connection with short or long-term follow-up after ACL surgery, will undergo a clinical assessment of their knee injury as part of standard care. This includes an assessment of knee joint laxity using both the Rolimeter and the Lachmeter, to allow for an assessment of agreement between the two methods.
Study NCT06233318 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine
Description: The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
Study NCT06233318 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pecto-intercostal Fascial Block with normal saline
Description: The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
Study NCT05400525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: YMETA
Description: 1 sachet containg a total of 3g i.e. 2.5g Galacto-oligosaccharides, 0.5g Bifidobacterium polysaccharides (daily)
Study NCT05400525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: 3g Maltodextrin (i.e. DE 10) daily
Study NCT06528028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ/AVI
Description: continuous infusion is used
Study NCT06528028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ/AVI
Description: 2h-infusion is used
Study NCT05709743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Within-Subjects Attentional Information
Description: Behavioral: Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
Study NCT06296719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chit-Chat
Description: Participants will receive the 2 sessions of the Chit-Chat intervention on a weekly basis.
Study NCT04897893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid monoglycerid (MAG-EPA)
Description: MAG-EPA is an omega-3 fatty acid classified in canada as a Natural Health Product (NHP). The NHP is approuved under the Natural Health Product number (NPN # 80050187).
Study NCT06424678 — intervention group
Intervention type: OTHER
Intervention: Only data collection in the Utstein template
Description: The intervention that we will carry out in both groups will consist of collecting data from the patient (age, sex and race), on cardiopulmonary arrest, cardiopulmonary resuscitation, and the results of cardiopulmonary resuscitation.
Study NCT05153291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bachmann's bundle lead placement
Description: Atrial lead placement at Bachmann's bundle area
Study NCT05153291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right atrial appendage lead placement
Description: Atrial lead placement in the right atrial appendage
Study NCT05915884 — intervention group
Intervention type: OTHER
Intervention: SGLT-2 inhibitors
Description: This study is an observational study. It is not planned to do an interventional activity.
Study NCT00724074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-Q PainBuster with Bupivacaine
Description: On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
Study NCT00724074 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study NCT05347030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: During the 12-week treatment, acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.
Study NCT05347030 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: During the 12-week treatment, Sham Acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.
Study NCT05528926 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-Violent Resistance
Description: The program's core features are parental self-control and emotional support. In the NVR program, parents recruit supporters to help them deal with their children's problematic behaviours. Developing emotional control means that the parent opposes non-violent resistance to his child's behaviour, not escalating the explosive situation.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion).
Study NCT05528926 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parent Management Training
Description: The gold-standard treatment for disruptive behaviour disorder in children and adolescents. The objective is to train parents to cope with the difficult situations they encounter, to teach them effective control strategies that are coherent and adapted to the 'deviant' behaviour of their children to reduce the intensity of events and their repercussions within the family.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion).
Study NCT05528926 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment As Usual
Description: The TAU group receives non-pharmacological and pharmacological therapies as usually provided in the participating centres but without having had a structured parent program in the last 6 months assessed at baseline, M1 and M3.
Study NCT05186350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP+ SpyGlass
Description: SpyGlass direct Vision guided laser lithotripsy
Study NCT05186350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESWL+ ERCP
Description: ESWL + Stone removal through ERCP
Study NCT06321237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus nerve stimulation for 8 weeks
Description: The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for 8 weeks
Study NCT06321237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation for the first 4 weeks
Description: The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for the first 4 weeks
Study NCT06321237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation for the last 4 weeks
Description: The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for the last 4 weeks
Study NCT06321237 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pseudostimulus
Description: The patient is given some electrical stimulation but not vagus nerve stimulation
Study NCT05951517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: MMF treat refractory gastrointestinal Henoch-Schönlein purpura
Study NCT04695639 — intervention group
Intervention type: OTHER
Intervention: Test of Arm Selective Control
Description: It will be used to assess selective voluntary motor control. It is a reliable and valid evaluation tool used to quantify and describe selective voluntary motor control in children with spastic cerebral palsy. The goal of the assessment is to systematically evaluate a person's ability to move the upper extremity with selective voluntary motor control by observing movement control, coordination, fluency, mirroring, and speed at each joint, and then assigning a grade, all in 'real time. Clinically this measure may guide the selection of medical, surgical, or therapy interventions and may improve outcome prognosis after brief training. Raters demonstrated excellent reliability in assessing upper extremity SVMC in a group of children with hemiplegic, diplegic, and quadriplegic CP using the Ttest of arm selective control
Study NCT04695639 — intervention group
Intervention type: OTHER
Intervention: Hand Held Dynamometer
Description: Hand held dynamometer (Camry Digital Hand Dynamometer Grip Strength, Model EH101-37, China) will be used to assess hand grip strength of the affected upper extremity. It is generally small, portable and relatively cheap reliable measurement instruments to measure muscle strength of the arm and hand in children with spastic cerebral pasly. It is used to measure strength; maximal voluntary isometric contraction; objectively in kilograms, pounds or newtons. Such devices have been proven to have good to excellent reliability in different populations. It represents an easily accessible way to assess muscle weakness in children with cerebral palsy and the overall reliability is considered to be good.
Study NCT04695639 — intervention group
Intervention type: OTHER
Intervention: Quality of Upper Extremity Skill Test
Description: It will be used to assess function of the affected upper extremity. It is a reliable and valid outcome measure designed to evaluate movement patterns and hand function in children with cerebral palsy. It is designed to be used with children who have neuromotor dysfunction with spasticity and has been validated with children from 18 months to 8 years of age.
Study NCT05117086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: Nutrition education and counseling on DASH diet, behavioral and lifestyle modifications
Study NCT05074563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REsOluTioN (Resilience Enhancement Online Training for Nurses)
Description: The online REsOluTioN training involves virtual or face-to-face mentorship sessions and facilitated online interactive group sessions on four topics (Building hardiness and maintaining a positive outlook, Intellectual flexibility and Emotional Intelligence; Achieving life balance and enabling spirituality and Reflective and critical thinking). The training will be of four-week duration. Over the four-week period, the training will comprise 4x120 minute facilitated online group sessions; 4x30 minute independent learning activities; and eight 3:1 online mentoring sessions delivered between 30 and 60 minutes at flexible timings.
Study NCT05074563 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Nurses randomised to the control group will only be invited to take part in the pre- and post- intervention surveys, but will not use the online training. However, after completing the survey, nurses will be given the opportunity to complete the pre-work and access the facilitated sessions of the training so that they can receive their CPD certificate.
Study NCT06483750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Systane iLux Treatment
Description: The Systane iLux is an approved thermal pulsation device to treat dry eye disease. The application of heat and compression to both eyelids melts meibum in the obstructed glands to restore the secretion and production of meibum to the eye. The Systane iLux will only be administered to the eye to undergo cataract surgery.
Study NCT03745664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Sodium Succinate
Description: During hospitalization, 40 mg of methylprednisolone (20 mg/ml) will be given intravenously twice a day (20 mg every 12 hours).
Study NCT03745664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution for Injection
Description: During hospitalization, 2 ml of Saline Solution for Injection will be given intravenously twice a day (2 ml every 12 hours).
Study NCT06507293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block
Description: Before the general anesthesia induction, paravertebral block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
Study NCT06507293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spiane plane block
Description: Before the general anesthesia induction, erector spinae plane block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
Study NCT05202561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNA tumor vaccine
Description: Subjects will receive single dose of RNA tumor vaccine injection on day 1, day 4, day 7, and day 14, each dose of 600 ng.
Study NCT05202561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNA tumor vaccine+Navuliumab
Description: RNA tumor vaccine+Navuliumab Subjects will receive maintenance therapy with a PD-1 inhibitor in addition to monotherapy with the RNA tumor vaccine injection. Subjects received a single dose of RNA vaccine injection on day 1, day 4, day 7, and day 14, with each dose of 600 ng. Inhibitors, accept the Navuliumab on day 14, the recommended dose is 3 mg/kg, intravenous injection every 2 weeks.
Study NCT06670040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: All TBS sessions will be delivered at the same site, intensity (up to 90% RMT), pattern and duration. Treatment conditions differ only in the amount of intracranial activation induced (i.e., negligible activation in sham condition). TBS sessions consist of triplet 50 Hz bursts repeated every 200 msec (5 Hz), delivered to the left DLPFC in an intermittent (2 seconds on/8 seconds off) pattern for a total of 600 pulses per session; duration of 3 minutes 9 seconds.
Study NCT06670040 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Sham
Description: We will use a robust sham technique that suitably replicates the sensory experience (auditory and peripheral activation) of active TBS with minimal intracranial activation. The Magstim Horizon™ sham coil will be utilized for treatment delivery. This sham coil is visually identical to the active coil and replicates the sounds and sensation of the magnetic stimulation. All sham treatment will be delivered at the same site, intensity (up to 90% RMT), pattern and duration. Treatment conditions differ only in the amount of intracranial activation induced (i.e., negligible activation in sham condition). TBS sessions consist of triplet 50 Hz bursts repeated every 200 msec (5 Hz), delivered to the left DLPFC in an intermittent (2 seconds on/8 seconds off) pattern for a total of 600 pulses per session; duration of 3 minutes 9 seconds
Study NCT06670547 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Description: Endoscopic retrograde cholangiopancreatography (ERCP)
Study NCT06669390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG11-2
Description: NG11-2 dose level will vary from 0.92 mg/mL to 5.5 mg/mL during the dose escalation process. The NG11-2 is given as an oral rinse.~Throughout the radiotherapy regimen, no more than 60 minutes prior to the completion of radiotherapy, on each weekday the patient will rinse their mouth with 12.5 ml of NG11-2 for between 90 \& 120 seconds duration, gargling twice for approximately three seconds each if possible during this period then expectorate the solution.
Study NCT06669598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Electromyostimulation
Description: The ETG group underwent in two 20-minute training sessions per week (12 weeks), with 72 hours of rest between sessions. Each session included aerobic activities such as rowing and treadmill exercises, combined with supervised WB-EMS stimulation. This stimu-lation utilised a rectangular waveform at 35 Hz, 350 μs, with continuous pulse dura-tion
Study NCT06669598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The CON group underwent three weekly training sessions for twelve weeks, con-sisting of 20 minutes of aerobic activity, performed on a treadmill and rowing machine, without the WB-EMS superimposition.
Study NCT06670352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD or BID, 24-weeks fixed dose.
Study NCT06670352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297 50mgBID
Description: 24-weeks fixed dose.
Study NCT06670352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297 100mgBID
Description: 24-weeks fixed dose.
Study NCT06670352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297 200mgQD
Description: 24-weeks fixed dose.